What was studied?
The trial randomized 529 participants with heart failure with preserved ejection fraction and obesity to semaglutide or placebo for 52 weeks.
What did the researchers report?
The semaglutide group had greater improvement in a heart-failure symptom score, greater weight reduction and better six-minute walk performance than the placebo group.
What are the limits?
The primary endpoints were symptoms and weight, not proof of longer survival. Results in this particular heart-failure population cannot be extended automatically to other forms of heart failure or to healthy individuals.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.